314 related articles for article (PubMed ID: 12605394)
21. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
22. Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis.
Ahmad S; Shen FH; Bleyer WA
Arch Intern Med; 1978 Jul; 138(7):1146-7. PubMed ID: 666479
[TBL] [Abstract][Full Text] [Related]
23. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
24. [Severe renal impairment of methotrexate elimination after high dose therapy].
Lawrenz-Wolf B; Wolfrom C; Frickel C; Fengler R; Wehinger H; Henze G
Klin Padiatr; 1994; 206(4):319-26. PubMed ID: 7967432
[TBL] [Abstract][Full Text] [Related]
25. [Delayed clearance of methotrexate in a patient with malignant lymphoma who developed renal failure].
Wakita A; Komatsu H; Banno S; Nitta M; Nagai H; Uchida T; Murase T; Nakahara Y; Tanaka M
Gan To Kagaku Ryoho; 1995 Feb; 22(2):285-8. PubMed ID: 7857106
[TBL] [Abstract][Full Text] [Related]
26. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
27. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function.
Hempel L; Misselwitz J; Fleck C; Kentouche K; Leder C; Appenroth D; Rost M; Zintl F
Med Pediatr Oncol; 2003 Jun; 40(6):348-54. PubMed ID: 12692801
[TBL] [Abstract][Full Text] [Related]
28. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
[TBL] [Abstract][Full Text] [Related]
29. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
30. Essential laboratory determinations for monitoring high-dose methotrexate treatment with citrovorum factor rescue.
Jürgens H; Ebell W; Bachmann R; Kupke I; Richter O; Andräs A; Göbel U
Pediatr Pharmacol (New York); 1983; 3(3-4):157-65. PubMed ID: 6610851
[TBL] [Abstract][Full Text] [Related]
31. High-dose methotrexate-doxycycline interaction.
Tortajada-Ituren JJ; Ordovás-Baines JP; Llopis-Salvia P; Jiménez-Torres NV
Ann Pharmacother; 1999; 33(7-8):804-8. PubMed ID: 10466909
[TBL] [Abstract][Full Text] [Related]
32. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
33. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.
Park JM; Moon CH; Lee MG
Res Commun Mol Pathol Pharmacol; 1996 Sep; 93(3):353-62. PubMed ID: 8896046
[TBL] [Abstract][Full Text] [Related]
35. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
36. Effect of methotrexate and folinic acid on skeletal growth in mice.
Iqbal MP; Ahmed M; Umer M; Mehboobali N; Qureshi AA
Acta Paediatr; 2003 Dec; 92(12):1438-44. PubMed ID: 14971796
[TBL] [Abstract][Full Text] [Related]
37. Prolonged accumulation of high-dose methotrexate in a case with large liver cysts.
Kawakami M; Omori H; Yamagami T; Soma T
Cancer Chemother Pharmacol; 2009 Aug; 64(3):619-22. PubMed ID: 19319534
[TBL] [Abstract][Full Text] [Related]
38. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
39. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma.
Thomson AH; Daly M; Knepil J; Harden P; Symonds P
Cancer Chemother Pharmacol; 1996; 38(6):566-70. PubMed ID: 8823500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
